Tiecheng Zhang

Tiecheng Zhang

Auto-generated profile, based on publicly available information

Tiecheng Zhang

Department of Medical Oncology, The Affiliated Huaian No.1 People's Hospital of Nanjing Medical University, Huai'an, 223300 Jiangsu, China

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 September 2017 in Cancer Biomarkers
Verified
Journal Article
Closed access
PDF file
RYRong Yao
Rong Yao
JPJuan Pu
Juan Pu
RFRuihua Fan
Ruihua Fan
WZWeiguo Zhu
Weiguo Zhu
XDXiaorong Ding
Xiaorong Ding
TZTiecheng Zhang
Tiecheng Zhang
Our study mainly investigated ubiquitin-specific protease 4 (USP4) expression in pathogenesis of esophageal cancer. The data showed significantly increased expression of USP4 in cancer tissues compared to that in para-carcinoma tissues (68.38% ± 25.6

7 December 2021 in Disease Markers
Verified
Journal Article
Open access
PDF file
RYRong Yao
Rong Yao
LZLeilei Zhou
Leilei Zhou
ZGZhongying Guo
Zhongying Guo
DZDahong Zhang
Dahong Zhang
TZTiecheng Zhang
Tiecheng Zhang
Objective. Precision medicine with molecular profiles has revolutionized the management of lung cancer contributing to improved prognosis. Herein, we aimed to uncover the gene expression profiling of transcription factors (TFs) in lung cancer as well as to develop a TF-based genomic model. Methods. We retrospectively curated lung cancer patients from public databases. Through comparing mRNA expression profiling between lung cancer and normal specimens, specific TFs were determined. Thereafter, a TF genomic model was developed with univariate Cox regression and stepwise multivariable Cox analyses, which was verified through the GSE72094 dataset. Gene set enrichment analyses (GSEA) were presented. Downstream targets of TFs were predicted with ChEA, JASPAR, and MotifMap projects, and their biological significance was investigated through the clusterProfiler algorithm. Results. In the TCGA cohort, we proposed a TF-based genomic model, comprised of SATB2, HLF, and NPAS2. Lung cancer individuals were remarkably stratified into high- and low-risk groups. Survival analyses uncovered that high-risk populations presented unfavorable survival outcomes. ROCs confirmed the excellent predictive potency in patients prognosis. Additionally, this model was an independent prognostic indicator in accordance with multivariate analyses. The clinical implication of the model was well verified in an independent dataset. High risk score was in relation to carcinogenic pathways. Downstream targets were characterized by immune and carcinogenic activation. Conclusion. The proposed TF genomic model acts as a promising marker for estimation of lung cancer patients outcomes. Prospective research is required for testing the clinical utility of the model in individualized management of lung cancer.